Study Summary
This trial is testing a new drug, NUV-868, for safety and efficacy in patients with advanced solid tumors. The drug will be taken orally, either as a monotherapy or in combination with other drugs olaparib or enzalutamide, in 28-day cycles. The trial will continue until the disease progresses, there are unacceptable side effects, the patient withdraws consent, or the trial is terminated.
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Castration-resistant Prostate Cancer
- Triple Negative Breast Cancer
- Breast Cancer
- Advanced Solid Tumors
- Ovarian Tumors
Treatment Effectiveness
Effectiveness Progress
Study Objectives
10 Primary · 0 Secondary · Reporting Duration: Every 4 weeks throughout study treatment, up to an average of 12 months (end of treatment)
Trial Safety
Safety Progress
Trial Design
6 Treatment Groups
Phase 1 Monotherapy Dose Escalation
1 of 6
Phase 1b Dose Escalation: NUV-868 + Enzalutamide
1 of 6
Phase 2b Combination Expansion: NUV-868 + Enzalutamide
1 of 6
Phase 2 Monotherapy Expansion
1 of 6
Phase 1b Dose Escalation: NUV-868 + Olaparib
1 of 6
Phase 2b Combination Expansion: NUV-868 + Olaparib
1 of 6
Experimental Treatment
246 Total Participants · 6 Treatment Groups
Primary Treatment: NUV-868 · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are people still able to sign up for this experiment?
"That is accurate. The information available on clinicaltrials.gov demonstrates that this study, which was initially posted on 3/29/2022, is still recruiting participants. 246 individuals are needed for the trial taking place at 7 different locations." - Anonymous Online Contributor
Are there any other locations where this experiment is taking place?
"Currently, there are 7 sites enrolling patients for this trial. The locations of these centres include Baltimore, Detroit, Huntersville and other cities. To reduce the amount of travel required, make sure to select the centre nearest you when enrolling." - Anonymous Online Contributor
How many people are eligible to participate in this research project?
"In order to run the study, 246 people who meet the clinical trial's requirements must be recruited. The sponsor, Nuvation Bio Inc., will manage and operate the trial from different locations which include Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland as well as Karmanos Cancer Institute in Detroit, Michigan." - Anonymous Online Contributor